Stefan Holdenrieder

Title: Innovations by Stefan Holdenrieder in Tumor Therapy

Introduction

Stefan Holdenrieder is a notable inventor based in Munich, Germany. He has made significant contributions to the field of medical diagnostics, particularly in the assessment of tumor therapies. With a total of 2 patents, his work focuses on the determination of apoptotic products in patients undergoing therapy.

Latest Patents

Holdenrieder's latest patents include methods for determining apoptotic products in samples taken from patients. One of his inventions concerns a method that correlates the concentration of apoptotic products with the effectiveness of therapy. This method is particularly useful for assessing the effectiveness of tumor therapy by determining the concentration of nucleosomes in serum samples. His inventions also extend to patients undergoing radiotherapy or chemotherapy, as well as those recovering from acute ischemic events or hypothermia treatment.

Career Highlights

Stefan Holdenrieder is associated with Roche Diagnostics GmbH, a leading company in the field of medical diagnostics. His work has been instrumental in advancing methods that provide critical insights into patient therapy effectiveness.

Collaborations

Holdenrieder has collaborated with notable colleagues such as Martin Busch and Heinz Bodenmueller, contributing to the development of innovative diagnostic methods.

Conclusion

Stefan Holdenrieder's contributions to the field of tumor therapy diagnostics highlight the importance of innovation in medical science. His patents reflect a commitment to improving patient outcomes through advanced diagnostic techniques.